0001193125-19-323093.txt : 20191226 0001193125-19-323093.hdr.sgml : 20191226 20191226083121 ACCESSION NUMBER: 0001193125-19-323093 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20191223 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20191226 DATE AS OF CHANGE: 20191226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDICAL PROPERTIES TRUST INC CENTRAL INDEX KEY: 0001287865 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32559 FILM NUMBER: 191308400 BUSINESS ADDRESS: STREET 1: 1000 UBRAN CENTER DRIVE STREET 2: SUITE 501 CITY: BIRMINGHAM STATE: AL ZIP: 35242 BUSINESS PHONE: 205-969-3755 MAIL ADDRESS: STREET 1: 1000 URBAN CENTER DRIVE STREET 2: SUITE 501 CITY: BIRMINGHAM STATE: AL ZIP: 35242 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MPT Operating Partnership, L.P. CENTRAL INDEX KEY: 0001524607 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-177186 FILM NUMBER: 191308399 BUSINESS ADDRESS: STREET 1: MEDICAL PROPERTIES TRUST, INC. STREET 2: 1000 URBAN CENTER DRIVE, SUITE 501 CITY: BIRMINGHAM STATE: AL ZIP: 35242 BUSINESS PHONE: 205-969-3755 MAIL ADDRESS: STREET 1: MEDICAL PROPERTIES TRUST, INC. STREET 2: 1000 URBAN CENTER DRIVE, SUITE 501 CITY: BIRMINGHAM STATE: AL ZIP: 35242 8-K 1 d118863d8k.htm 8-K 8-K
false00012878650001524607MEDICAL PROPERTIES TRUST INCALAL 0001287865 2019-12-23 2019-12-23 0001287865 mpw:MptOperatingPartnershipLpMember 2019-12-23 2019-12-23
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 23, 2019
 
MEDICAL PROPERTIES TRUST, INC.
MPT OPERATING PARTNERSHIP, L.P.
(Exact Name of Registrant as Specified in Charter)
 
         
Maryland
Delaware
 
001-32559
333-177186
 
20-0191742
20-0242069
(State or other jurisdiction of
incorporation or organization)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)
 
 
 
 
 
 
 
 
     
1000 Urban Center Drive, Suite 501
Birmingham, AL
 
35242
(Address of principal executive offices)
 
(Zip Code)
 
 
 
 
 
 
 
 
Registrant’s telephone number, including area code: (205) 969-3755
N/A
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
 
 
 
 
 
 
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
 
 
 
 
 
 
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
 
 
 
 
 
 
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
 
 
Securities registered pursuant to Section 12(b) of the Securities Act:
         
Title of each class
 
Trading
Symbol
 
Name of each exchange
on which registered
Common Stock,
par value $0.001 per share,
of Medical Properties Trust, Inc.
 
MPW
 
The New York Stock Exchange
 
 
 
 
 
 
 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
     
Medical Properties Trust, Inc.
 
Emerging growth company  
     
MPT Operating Partnership, L.P.
 
Emerging growth company  
 
 
 
 
 
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
     
Medical Properties Trust, Inc.
 
     
MPT Operating Partnership, L.P.
 
 
 
 
 
 
 
 
 
 
 
 
 

This Current Report on Form
8-K
is filed by Medical Properties Trust, Inc., a Maryland corporation (the “Company”), and MPT Operating Partnership, L.P., a Delaware limited partnership through which the Company conducts substantially all of its operations (the “Operating Partnership”). Through one of its wholly-owned subsidiaries, the Company serves as the sole general partner of the Operating Partnership. Unless otherwise indicated or unless the context requires otherwise, references to “we” and “our” refer to the Company, the Operating Partnership and any other subsidiaries thereof.
Item 1.01.
Entry into a Material Definitive Agreement.
 
 
 
 
 
 
 
 
Acquisition of BMI Portfolio
On December 23, 2019, the Operating Partnership entered into definitive agreements pursuant to which certain of its subsidiaries will acquire a portfolio of 30 acute care hospitals located throughout the United Kingdom currently operated by BMI Healthcare Ltd. (“BMI”) and owned by an affiliate of BMI, for approximately £1.5 billion, or approximately $2.0 billion (the “BMI Acquisition”). In a related transaction, affiliates of Circle Health Ltd. (“Circle”) entered into definitive agreements to acquire BMI and assume operations of its 52 facilities in the United Kingdom. Circle has been one of the Company’s tenants since 2014.
Upon closing of the transactions, we will lease back the hospitals to affiliates of Circle under 30 cross-defaulted leases guaranteed by Circle. The leases will each have an initial fixed term to 2050, with two five-year extension options and annual rent escalators linked to UK consumer price inflation.
The table below sets forth certain details with respect to the hospitals in the BMI portfolio that we are acquiring:
                                 
Hospital
 
City
 
 
Form of
Investment
 
 
Hospital
Type
 
 
Licensed
Beds
 
London Independent
 
 
London
 
 
 
Fee simple
 
 
 
Acute
 
 
 
73
 
Blackheath
 
 
London
 
 
 
Fee simple
 
 
 
Acute
 
 
 
68
 
Alexandra
 
 
Cheadle
 
 
 
Fee simple
 
 
 
Acute
 
 
 
171
 
Ross Hall
 
 
Glasgow
 
 
 
Fee simple
 
 
 
Acute
 
 
 
101
 
Highfield
 
 
Rochdale
 
 
 
Fee simple
 
 
 
Acute
 
 
 
47
 
Beaumont
 
 
Bolton
 
 
 
Fee simple
 
 
 
Acute
 
 
 
34
 
Droitwich
 
 
Droitwich Spa
 
 
 
Long leasehold
 
 
 
Acute
 
 
 
56
 
Priory
 
 
Edgbaston
 
 
 
Fee simple and long leasehold
 
 
 
Acute
 
 
 
118
 
Hampshire Clinic
 
 
Basingstoke
 
 
 
Fee simple
 
 
 
Acute
 
 
 
65
 
Sarum Road
 
 
Winchester
 
 
 
Fee simple
 
 
 
Acute
 
 
 
48
 
Albyn
 
 
Aberdeen
 
 
 
Fee simple
 
 
 
Acute
 
 
 
28
 
Winterbourne
 
 
Dorchester
 
 
 
Long leasehold
 
 
 
Acute
 
 
 
38
 
Hendon
 
 
London
 
 
 
Fee simple
 
 
 
Acute
 
 
 
30
 
Goring Hall
 
 
Worthing
 
 
 
Fee simple
 
 
 
Acute
 
 
 
37
 
Werndale
 
 
Carmarthen
 
 
 
Fee simple
 
 
 
Acute
 
 
 
27
 
Bath Clinic
 
 
Bath
 
 
 
Fee simple
 
 
 
Acute
 
 
 
67
 
Ridgeway
 
 
Swindon
 
 
 
Fee simple
 
 
 
Acute
 
 
 
50
 
Beardwood
 
 
Blackburn
 
 
 
Fee simple
 
 
 
Acute
 
 
 
18
 
Thornbury
 
 
Sheffield
 
 
 
Fee simple
 
 
 
Acute
 
 
 
77
 
Park
 
 
Arnold
 
 
 
Fee simple
 
 
 
Acute
 
 
 
85
 
Clementine Churchill
 
 
Harrow
 
 
 
Fee simple
 
 
 
Acute
 
 
 
141
 
Mount Alvernia
 
 
Guildford
 
 
 
Fee simple
 
 
 
Acute
 
 
 
76
 
Chaucer
 
 
Canterbury
 
 
 
Fee simple
 
 
 
Acute
 
 
 
55
 
Chelsfield Park
 
 
Orpington
 
 
 
Fee simple
 
 
 
Acute
 
 
 
36
 
Shirley Oaks
 
 
Croydon
 
 
 
Fee simple
 
 
 
Acute
 
 
 
42
 
Sloane
 
 
Beckenham
 
 
 
Fee simple
 
 
 
Acute
 
 
 
32
 
Princess Margaret
 
 
Windsor
 
 
 
Fee simple
 
 
 
Acute
 
 
 
78
 
Chiltern
 
 
Great Missenden
 
 
 
Fee simple
 
 
 
Acute
 
 
 
66
 
Saxon Clinic
 
 
Milton Keynes
 
 
 
Fee simple
 
 
 
Acute
 
 
 
37
 
Manor
 
 
Biddenham
 
 
 
Fee simple
 
 
 
Acute
 
 
 
23
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Licensed Beds
 
 
 
 
 
 
 
 
1,824
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Subject to customary closing conditions, the Company expects to consummate the BMI Acquisition in the first quarter of 2020.
The BMI Acquisition was documented pursuant to the terms of a share purchase agreement, dated December 23, 2019, between GHG Holdco 3 Limited, an affiliate of BMI and indirect owner of the properties, as seller, and Medical Properties Trust Limited, our affiliate, as purchaser (the “Share Purchase Agreement”). The Share Purchase Agreement contemplates that five
non-core
properties, with an aggregate purchase price of less than £10.0 million, owned by the seller and not included in the portfolio of properties listed above will be sold to third parties either prior to or following the closing.
The Company intends to finance the BMI Acquisition with cash on hand, including proceeds from recent U.S. dollar equity and sterling-denominated bond offerings and borrowings under an unsecured sterling-denominated term loan facility. We cannot assure you that the BMI Acquisition will be completed on the terms described herein or at all.
Item 7.01.
Regulation FD Disclosure.
 
 
 
 
 
 
 
 
On December 23, 2019, the Company issued a press release announcing the BMI Acquisition described in Item 1.01 of this Current Report on Form
8-K.
A copy of the press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.
The information contained in this Item 7.01 and exhibits thereto is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise. The information in this Item 7.01, including the exhibit thereto, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended (the “Securities Act”), or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.
Forward-Looking Statements
This Current Report on Form
8-K
contains certain “forward-looking” statements as defined by Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements can generally be identified by the use of forward-looking words such as “may”, “will”, “would”, “could”, “expect”, “intend”, “plan”, “aim”, “estimate”, “target”, “anticipate”, “believe”, “continue”, “objectives”, “outlook”, “guidance” or other similar words, and include statements regarding the Company’s plans, strategies, objectives, targets, future expansion and development activities and expected financial performance that are not historical facts. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results of the Company or future events to differ materially from those expressed in or underlying such forward-looking statements, including, without limitation: the satisfaction of all conditions to, and the closing of the BMI Acquisition and related transactions on the terms contemplated or at all; the ability of the Company’s tenants to meet the terms of their agreements; expected payout ratio; the amount of acquisitions of healthcare real estate, if any; capital markets conditions; the repayment of debt arrangements; statements concerning the additional income to the Company as a result of ownership interests in certain hospital operations and the timing of such income; the payment of future dividends, if any; completion of additional debt or equity arrangements, and additional investments; national and international economic, business, real estate and other market conditions; the competitive environment in which the Company operates; the execution of the Company’s business plan; financing risks; the Company’s ability to maintain its status as a real estate investment trust for federal income tax purposes; acquisition and development risks; potential environmental and other liabilities; and other factors affecting the real estate industry generally or healthcare real estate in particular; and the value of our real estate assets, which may limit our ability to dispose of assets at attractive prices or obtain or maintain equity or debt financing secured by our properties or on an unsecured basis, and the factors referenced under the section captioned “Item 1.A Risk Factors” in the Annual Report on Form
10-K
of the Company and the Operating Partnership for the year ended December 31, 2018 and the Quarterly Report on Form
10-Q
of the Company and the Operating Partnership for the quarter ended September 30, 2019, and other risks described in documents subsequently filed by the Company or the Operating Partnership from time to time with the Securities and Exchange Commission.
 
 

Item 9.01.
Financial Statements and Exhibits.
 
 
 
 
 
 
 
 
(d)    Exhibits
         
Exhibit
    No.    
 
 
Description
         
 
99.1
   
         
 
104
   
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
 
 
 
 
 
 

SIGNATURES
Pursuant to the requirements of the Exchange Act, the registrants have duly caused this report to be signed on their behalf by the undersigned hereunto duly authorized.
     
MEDICAL PROPERTIES TRUST, INC.
     
By:
 
/s/ R. Steven Hamner
Name:
 
R. Steven Hamner
Title:
 
Executive Vice President and Chief Financial Officer
 
MPT OPERATING PARTNERSHIP, L.P.
     
By:
 
/s/ R. Steven Hamner
Name:
 
R. Steven Hamner
Title:
 
Executive Vice President and Chief
Financial Officer of the sole member of
the general partner of MPT Operating 
Partnership, L.P.
 
 
 
 
 
 
 
 
Date: December 2
6
, 2019
 
EX-99.1 2 d118863dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

 

  

Contact: Tim Berryman

  

Director – Investor Relations

  

Medical Properties Trust, Inc.

  

(205) 969-3755

tberryman@medicalpropertiestrust.com

MEDICAL PROPERTIES TRUST ANNOUNCES £1.5 BILLION ACQUISITION OF 30 UK HOSPITAL FACILITIES

Portfolio Comprised of Invaluable Hospitals Essential to Meet Growing Demand for UK Healthcare

Company Increases Annual Run-Rate Estimates of Per Share Net Income and Normalized FFO

BIRMINGHAM, Ala. — December 23, 2019 — Medical Properties Trust, Inc. (“MPT” or the “Company”) (NYSE: MPW), today announced that it has entered into definitive agreements to acquire the real estate of 30 acute care hospital facilities located throughout the United Kingdom for an aggregate purchase price of approximately £1.5 billion, or approximately $2.0 billion. The facilities are leased under long-term inflation protected net leases to affiliates of BMI Healthcare (“BMI”), the largest private operator of acute hospitals in the United Kingdom. In a related transaction, affiliates of Circle Health (“Circle”) are to acquire BMI and assume operations of its 52 facilities in the United Kingdom. Circle, an award winning operator of UK acute hospitals and successful MPT tenant, has committed to a multi-million pound program of investment in facility infrastructure, technology and people as part of the transaction.

The lease arrangement is expected to provide a GAAP-basis yield of 8.9%. The acquisition was underwritten by MPT to provide initial lease payment coverages of approximately 2.0 times recent EBITDAR, with the expectation of expanding coverage as Circle implements its strategic and operational initiatives. The hospitals will be leased under a master lease structure guaranteed by Circle with an initial fixed term of 30 years, two 5-year extension options, and annual rent escalators linked to UK consumer price inflation. MPT expects to fund the acquisition with cash on hand, including proceeds from recent U.S. dollar equity and sterling-denominated bond offerings and borrowings under an unsecured sterling-denominated term loan facility. The transaction is expected to close in the first quarter of 2020 subject to customary closing conditions.

“These hospitals represent a unique collection of facilities that are critical to the delivery of acute health services across the United Kingdom,” said Edward K. Aldag, Jr., MPT’s Chairman, President and CEO. “We are confident in the growing opportunities for private hospital operators in UK healthcare. We look forward to advancing our relationship with our UK operators in contributing to improved facility efficiency, quality of care and health outcomes for all hospital patients throughout the United Kingdom.”

Benefits of Transaction

 

   

Achieves Immediate Accretion. The strong cash and GAAP returns, along with MPT’s attractive cost of capital will result in immediate improvement of per share net income and funds from operations.

 

1


   

Increases UK Footprint. This transaction significantly increases the Company’s footprint throughout the United Kingdom, resulting in a total investment of approximately $2.5 billion in the UK. The UK market is highly attractive for future growth with its appealing demographics and unwavering governmental and social commitment to providing healthcare to its population.

 

   

Reduces Tenant Concentration. MPT’s total gross assets increases to approximately $16.2 billion and exposure to its largest tenant declines to 25%, down from almost 40% at the beginning of 2019.

Based on year-to-date transactions in 2019, along with an assumed capital structure that results in a net debt to EBITDA ratio of approximately 5.5 times, MPT expects an annual run-rate of $1.24 to $1.27 per diluted share for net income and $1.65 to $1.68 per diluted share for Normalized Funds from Operations (“NFFO”).

A reconciliation of NFFO guidance to net income and a reconciliation of pro forma total gross assets to total assets are included in the financial tables accompanying this press release.

These estimates do not include the effects, if any, of unexpected real estate operating costs, changes in accounting pronouncements, litigation costs, debt refinancing costs, acquisition costs, currency exchange rate movements, interest rate hedging activities, write-offs of straight-line rent or other non-recurring or unplanned transactions. These estimates may change if the Company acquires or sells assets in amounts that are different from estimates, market interest rates change, debt is refinanced, new shares are issued, additional debt is incurred, other operating expenses vary, income from our equity investments vary from expectations, or existing leases do not perform in accordance with their terms.

MPT will be acquiring the real estate portfolio from an affiliate of BMI pursuant to the terms of a share purchase agreement, which also contemplates that an additional five non-core properties will be disposed of either prior to or following the closing.

About Medical Properties Trust, Inc.

Medical Properties Trust, Inc. is a self-advised real estate investment trust formed in 2003 to acquire and develop net-leased hospital facilities. From its inception in Birmingham, Alabama, the Company has grown to become one of the world’s largest owners of hospitals with 390 facilities and approximately 42,000 licensed beds in eight countries and across three continents. MPT’s financing model facilitates acquisitions and recapitalizations and allows operators of hospitals to unlock the value of their real estate assets to fund facility improvements, technology upgrades and other investments in operations. For more information, please visit the Company’s website at www.medicalpropertiestrust.com.

The statements in this press release that are forward looking are based on current expectations and actual results or future events may differ materially. Words such as “expects,” “believes,” “anticipates,” “intends,” “will,” “should” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results of the Company or future events to differ materially from those expressed in or underlying such forward-looking statements, including without limitation: the satisfaction of all conditions, and the timely closing (if at all) of the transactions described above; annual run-rate net income and NFFO per share; the amount of acquisitions of healthcare real estate, if any; results from potential sales and joint venture arrangements, if any; capital markets conditions; estimated leverage metrics; the repayment of debt arrangements; statements concerning the additional income to the Company as a result of ownership interests in equity investments and the timing of such income; the payment of future dividends, if any;

 

2


completion of additional debt arrangements, and additional investments; national and international economic, business, real estate and other market conditions; the competitive environment in which the Company operates; the execution of the Company’s business plan; financing risks; the Company’s ability to maintain its status as a REIT for income tax purposes; acquisition and development risks; potential environmental and other liabilities; and other factors affecting the real estate industry generally or healthcare real estate in particular. For further discussion of the factors that could affect outcomes, please refer to the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 and as updated by the Company’s subsequently filed Quarterly Reports on Form 10-Q and other SEC filings. Except as otherwise required by the federal securities laws, the Company undertakes no obligation to update the information in this press release.

# # #

 

3


MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES

Annual Run-Rate Guidance Reconciliation

(Unaudited)

 

     Annual Run-Rate Guidance - Per  Share(1)  
     Low      High  

Net income attributable to MPT common stockholders

   $ 1.24      $ 1.27  

Participating securities’ share in earnings

     —          —    
  

 

 

    

 

 

 

Net income, less participating securities’ share in earnings

   $ 1.24      $ 1.27  

Depreciation and amortization

     0.41        0.41  
  

 

 

    

 

 

 

Funds from operations

   $ 1.65      $ 1.68  

Other adjustments

     —          —    
  

 

 

    

 

 

 

Normalized funds from operations

   $ 1.65      $ 1.68  
  

 

 

    

 

 

 

 

(1)

The guidance is based on current expectations and actual results or future events may differ materially from those expressed in this table, which is a forward-looking statement within the meaning of the federal securities laws. Please refer to the forward-looking statement included in this press release and our filings with the Securities and Exchange Commission for a discussion of risk factors that affect our performance.

Pro Forma Total Gross Assets

(Unaudited)

 

     September 30, 2019  

Total Assets

   $ 12,452,153  

Add:

  

Completed investments since September 30, 2019, the BMI acquisition and committed developments and building improvement projects(2)

     2,962,028  

Accumulated depreciation and amortization

     571,589  

Incremental gross assets of our joint ventures(3)

     530,593  

Cash proceeds from November 2019 equity offering

     1,026,519  

Net cash proceeds from November 2019 sterling bond offering and other sterling debt

     1,629,543  

Less:

  

Cash used for funding transactions included above

     (2,977,028
  

 

 

 

Pro Forma Total Gross Assets(4)

   $ 16,195,397  
  

 

 

 

 

(2)

Reflects commitments to invest in 30 facilities in the United Kingdom and to finance the development of a facility in Texas, as well as investments in 10 facilities in the United States, and certain other facilities.

(3)

Adjustment to reflect our share of our joint ventures’ gross assets.

(4)

Pro forma total gross assets is total assets before accumulated depreciation/amortization and assumes all real estate binding commitments on new investments and unfunded amounts on development deals and commenced capital improvement projects are fully funded. We believe pro forma total gross assets is useful to investors as it provides a more current view of our portfolio and allows for a better understanding of our concentration levels as our binding commitments close and our other commitments are fully funded.

EX-101.SCH 3 mpw-20191223.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 4 mpw-20191223_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 5 mpw-20191223_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 mpw-20191223_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 7 mpw-20191223_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 8 g118863g1224055943474.jpg GRAPHIC begin 644 g118863g1224055943474.jpg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end EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-19-323093-xbrl.zip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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 2 97 1 false 1 0 false 0 false false R1.htm 1001 - Document - Cover Page Sheet http://www.medicalpropertiestrust.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports d118863d8k.htm d118863dex991.htm mpw-20191223.xsd mpw-20191223_cal.xml mpw-20191223_def.xml mpw-20191223_lab.xml mpw-20191223_pre.xml http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d118863d8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 2, "dts": { "calculationLink": { "local": [ "mpw-20191223_cal.xml" ] }, "definitionLink": { "local": [ "mpw-20191223_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "d118863d8k.htm" ] }, "labelLink": { "local": [ "mpw-20191223_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "mpw-20191223_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "mpw-20191223.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 6, "total": 6 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 1, "memberStandard": 0, "nsprefix": "mpw", "nsuri": "http://www.medicalpropertiestrust.com/20191223", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d118863d8k.htm", "contextRef": "P12_23_2019To12_23_2019", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "1001 - Document - Cover Page", "role": "http://www.medicalpropertiestrust.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d118863d8k.htm", "contextRef": "P12_23_2019To12_23_2019", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 1, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "mpw_MptOperatingPartnershipLpMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "MPT Operating Partnership LP [Member].", "label": "MPT Operating Partnership LP [Member]", "terseLabel": "MPT Operating Partnership LP [Member]" } } }, "localname": "MptOperatingPartnershipLpMember", "nsuri": "http://www.medicalpropertiestrust.com/20191223", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "xbrltype": "domainItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 16 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Cover Page
Dec. 23, 2019
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Entity Central Index Key 0001287865
Document Period End Date Dec. 23, 2019
Entity Registrant Name MEDICAL PROPERTIES TRUST INC
Entity File Number 001-32559
Entity Incorporation, State or Country Code MD
Entity Tax Identification Number 20-0191742
Entity Address, Address Line One 1000 Urban Center Drive
Entity Address, Address Line Two Suite 501
Entity Address, City or Town Birmingham
Entity Address, State or Province AL
Entity Address, Postal Zip Code 35242
City Area Code 205
Local Phone Number 969-3755
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Title of 12(b) Security Common Stock, par value $0.001 per share, of Medical Properties Trust, Inc.
Trading Symbol MPW
Security Exchange Name NYSE
MPT Operating Partnership LP [Member]  
Document Information [Line Items]  
Entity Central Index Key 0001524607
Entity Registrant Name MPT OPERATING PARTNERSHIP, L.P.
Entity File Number 333-177186
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 20-0242069
Entity Address, Address Line One 1000 Urban Center Drive
Entity Address, Address Line Two Suite 501
Entity Address, City or Town Birmingham
Entity Address, State or Province AL
Entity Address, Postal Zip Code 35242
City Area Code 205
Local Phone Number 969-3755
Entity Emerging Growth Company false
XML 18 d118863d8k_htm.xml IDEA: XBRL DOCUMENT 0001287865 2019-12-23 2019-12-23 0001287865 mpw:MptOperatingPartnershipLpMember 2019-12-23 2019-12-23 false 0001287865 0001524607 MEDICAL PROPERTIES TRUST INC AL AL 8-K 2019-12-23 MPT OPERATING PARTNERSHIP, L.P. MD DE 001-32559 333-177186 20-0191742 20-0242069 1000 Urban Center Drive 1000 Urban Center Drive Suite 501 Suite 501 Birmingham Birmingham 35242 35242 205 205 969-3755 969-3755 false false false false Common Stock, par value $0.001 per share, of Medical Properties Trust, Inc. MPW NYSE false false